Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + bortezomib + dexamethasone vs bortezomib + dexamethasone in relapsed/refractory multiple myeloma (China)
CTR20170772Phase 3Completed
- Sponsor
- Cilag
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab in multiple myeloma (MM), sponsored by Cilag. Started Nov 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20170772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170772.